Dimitri Karmpaliotis1, Aris Karatasakis1, Khaldoon Alaswad1, Farouc A Jaffer1, Robert W Yeh1, R Michael Wyman1, William L Lombardi1, J Aaron Grantham1, David E Kandzari1, Nicholas J Lembo1, Anthony Doing1, Mitul Patel1, John N Bahadorani1, Jeffrey W Moses1, Ajay J Kirtane1, Manish Parikh1, Ziad A Ali1, Sanjog Kalra1, Phuong-Khanh J Nguyen-Trong1, Barbara A Danek1, Judit Karacsonyi1, Bavana V Rangan1, Michele K Roesle1, Craig A Thompson1, Subhash Banerjee1, Emmanouil S Brilakis2. 1. From the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, New York (D.K., J.W.M., A.J.K., M.P., Z.A.A., S.K.); Department of Cardiology, VA North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (A.K., P.-K.J.N.-T., B.A.D., J.K., B.V.R., M.K.R., S.B., E.S.B.); Department of Cardiology, Henry Ford Hospital, Detroit, MI (K.A.); Department of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston (F.A.J.); CardioVascular Institute at Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA (R.W.Y.); Lundquist Cardiovascular Institute, Torrance Memorial Medical Center, CA (R.M.W.); Cardiovascular Center, PeaceHealth St. Joseph Medical Center, Bellingham, WA (W.L.L.); Department of Interventional Cardiology, Mid America Heart Institute, Kansas City, MO (J.A.G.); Department of Interventional Cardiology, Piedmont Heart Institute, Atlanta, GA (D.E.K., N.J.L.); Department of Cardiology, Medical Center of the Rockies, Loveland, CO (A.D.); Division of Cardiovascular Medicine, VA San Diego Healthcare System and University of California (M.P., J.N.B.); and Boston Scientific, Natick, MA (C.A.T.). 2. From the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, New York (D.K., J.W.M., A.J.K., M.P., Z.A.A., S.K.); Department of Cardiology, VA North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (A.K., P.-K.J.N.-T., B.A.D., J.K., B.V.R., M.K.R., S.B., E.S.B.); Department of Cardiology, Henry Ford Hospital, Detroit, MI (K.A.); Department of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston (F.A.J.); CardioVascular Institute at Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA (R.W.Y.); Lundquist Cardiovascular Institute, Torrance Memorial Medical Center, CA (R.M.W.); Cardiovascular Center, PeaceHealth St. Joseph Medical Center, Bellingham, WA (W.L.L.); Department of Interventional Cardiology, Mid America Heart Institute, Kansas City, MO (J.A.G.); Department of Interventional Cardiology, Piedmont Heart Institute, Atlanta, GA (D.E.K., N.J.L.); Department of Cardiology, Medical Center of the Rockies, Loveland, CO (A.D.); Division of Cardiovascular Medicine, VA San Diego Healthcare System and University of California (M.P., J.N.B.); and Boston Scientific, Natick, MA (C.A.T.). esbrilakis@gmail.com.
Abstract
BACKGROUND: We sought to examine the efficacy and safety of chronic total occlusion percutaneous coronary intervention using the retrograde approach. METHODS AND RESULTS: We compared the outcomes of the retrograde versus antegrade-only approach to chronic total occlusion percutaneous coronary intervention among 1301 procedures performed at 11 experienced US centers between 2012 and 2015. The mean age was 65.5±10 years, and 84% of the patients were men with a high prevalence of diabetes mellitus (45%) and previous coronary artery bypass graft surgery (34%). Overall technical and procedural success rates were 90% and 89%, respectively, and in-hospital major adverse cardiovascular events occurred in 31 patients (2.4%). The retrograde approach was used in 539 cases (41%), either as the initial strategy (46%) or after a failed antegrade attempt (54%). When compared with antegrade-only cases, retrograde cases were significantly more complex, both clinically (previous coronary artery bypass graft surgery prevalence, 48% versus 24%; P<0.001) and angiographically (mean Japan-chronic total occlusion score, 3.1±1.0 versus 2.1±1.2; P<0.001) and had lower technical success (85% versus 94%; P<0.001) and higher major adverse cardiovascular events (4.3% versus 1.1%; P<0.001) rates. On multivariable analysis, the presence of suitable collaterals, no smoking, no previous coronary artery bypass graft surgery, and left anterior descending artery target vessel were independently associated with technical success using the retrograde approach. CONCLUSIONS: The retrograde approach is commonly used in contemporary chronic total occlusion percutaneous coronary intervention, especially among more challenging lesions and patients. Although associated with lower success and higher major adverse cardiovascular event rates in comparison to antegrade-only crossing, retrograde percutaneous coronary intervention remains critical for achieving overall high success rates.
BACKGROUND: We sought to examine the efficacy and safety of chronic total occlusion percutaneous coronary intervention using the retrograde approach. METHODS AND RESULTS: We compared the outcomes of the retrograde versus antegrade-only approach to chronic total occlusion percutaneous coronary intervention among 1301 procedures performed at 11 experienced US centers between 2012 and 2015. The mean age was 65.5±10 years, and 84% of the patients were men with a high prevalence of diabetes mellitus (45%) and previous coronary artery bypass graft surgery (34%). Overall technical and procedural success rates were 90% and 89%, respectively, and in-hospital major adverse cardiovascular events occurred in 31 patients (2.4%). The retrograde approach was used in 539 cases (41%), either as the initial strategy (46%) or after a failed antegrade attempt (54%). When compared with antegrade-only cases, retrograde cases were significantly more complex, both clinically (previous coronary artery bypass graft surgery prevalence, 48% versus 24%; P<0.001) and angiographically (mean Japan-chronic total occlusion score, 3.1±1.0 versus 2.1±1.2; P<0.001) and had lower technical success (85% versus 94%; P<0.001) and higher major adverse cardiovascular events (4.3% versus 1.1%; P<0.001) rates. On multivariable analysis, the presence of suitable collaterals, no smoking, no previous coronary artery bypass graft surgery, and left anterior descending artery target vessel were independently associated with technical success using the retrograde approach. CONCLUSIONS: The retrograde approach is commonly used in contemporary chronic total occlusion percutaneous coronary intervention, especially among more challenging lesions and patients. Although associated with lower success and higher major adverse cardiovascular event rates in comparison to antegrade-only crossing, retrograde percutaneous coronary intervention remains critical for achieving overall high success rates.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Khaldoon Alaswad; Rohan V Menon; Georgios Christopoulos; William L Lombardi; Dimitri Karmpaliotis; J Aaron Grantham; Steven P Marso; Michael R Wyman; Nagendra R Pokala; Siddharth M Patel; Anna P Kotsia; Bavana V Rangan; Nicholas Lembo; David Kandzari; James Lee; Anna Kalynych; Harold Carlson; Santiago A Garcia; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: Catheter Cardiovasc Interv Date: 2015-02-03 Impact factor: 2.692
Authors: Craig A Thompson; John E Jayne; John F Robb; Bruce J Friedman; Aaron V Kaplan; Bruce D Hettleman; Nathaniel W Niles; William L Lombardi Journal: JACC Cardiovasc Interv Date: 2009-09 Impact factor: 11.195
Authors: Georgios Christopoulos; Dimitri Karmpaliotis; Khaldoon Alaswad; Robert W Yeh; Farouc A Jaffer; R Michael Wyman; William L Lombardi; Rohan V Menon; J Aaron Grantham; David E Kandzari; Nicholas Lembo; Jeffrey W Moses; Ajay J Kirtane; Manish Parikh; Philip Green; Matthew Finn; Santiago Garcia; Anthony Doing; Mitul Patel; John Bahadorani; Muhammad Nauman J Tarar; Georgios E Christakopoulos; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: Int J Cardiol Date: 2015-06-27 Impact factor: 4.164
Authors: Dimitri Karmpaliotis; Tesfaldet T Michael; Emmanouil S Brilakis; Aristotelis C Papayannis; Daniel L Tran; Ben L Kirkland; Nicholas Lembo; Anna Kalynych; Harold Carlson; Subhash Banerjee; William Lombardi; David E Kandzari Journal: JACC Cardiovasc Interv Date: 2012-12 Impact factor: 11.195
Authors: Tesfaldet T Michael; Dimitri Karmpaliotis; Emmanouil S Brilakis; Eric Fuh; Vishal G Patel; Owen Mogabgab; Mohammed Alomar; Ben L Kirkland; Nicholas Lembo; Anna Kalynych; Harold Carlson; Subhash Banerjee; William Lombardi; David E Kandzari Journal: Am J Cardiol Date: 2013-05-11 Impact factor: 2.778
Authors: Tesfaldet T Michael; Dimitri Karmpaliotis; Emmanouil S Brilakis; Shuaib M Abdullah; Ben L Kirkland; Katrina L Mishoe; Nicholas Lembo; Anna Kalynych; Harold Carlson; Subhash Banerjee; William Lombardi; David E Kandzari Journal: Heart Date: 2013-04-18 Impact factor: 5.994
Authors: Kathleen Kearney; Ravi S Hira; Robert F Riley; Arun Kalyanasundaram; William L Lombardi Journal: Curr Atheroscler Rep Date: 2017-04 Impact factor: 5.113
Authors: Lei Song; Akiko Maehara; Matthew T Finn; Sanjog Kalra; Jeffrey W Moses; Manish A Parikh; Ajay J Kirtane; Michael B Collins; Tamim M Nazif; Khady N Fall; Raja Hatem; Ming Liao; Tiffany Kim; Philip Green; Ziad A Ali; Candido Batres; Martin B Leon; Gary S Mintz; Dimitri Karmpaliotis Journal: JACC Cardiovasc Interv Date: 2017-05-22 Impact factor: 11.195
Authors: Eugene B Wu; Hsien-Li Kao; Sidney Lo; Soo Teik Lim; Lei Ge; Ji-Yan Chen; Jie Qian; Seung-Whan Lee; Scott A Harding; Etsuo Tsuchikane Journal: AsiaIntervention Date: 2020-07-20
Authors: Barbara Anna Danek; Aris Karatasakis; Dimitri Karmpaliotis; Khaldoon Alaswad; Robert W Yeh; Farouc A Jaffer; Mitul P Patel; Ehtisham Mahmud; William L Lombardi; Michael R Wyman; J Aaron Grantham; Anthony Doing; David E Kandzari; Nicholas J Lembo; Santiago Garcia; Catalin Toma; Jeffrey W Moses; Ajay J Kirtane; Manish A Parikh; Ziad A Ali; Judit Karacsonyi; Bavana V Rangan; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: J Am Heart Assoc Date: 2016-10-11 Impact factor: 5.501